SEC Form 4
Vaxcyte, Inc. (PCVX) insider trading
In the 12 months to Oct 26, 2026, 5 PCVX insiders reported open-market sales of $12.4M across 23 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $12.4M
- 23 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 19 of 23
- $11.0M of $12.4M sold (89%)
Who traded PCVX, and when
- Sale
- Sale, pre-arranged (10b5-1)
PCVX daily close from Oct 27, 2025 to Oct 26, 2026, between $40.32 and $73.82, last $59.58. 23 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Grant Pickering, CHIEF EXECUTIVE OFFICER: sold $3.6M across 3 filings, first filed Jun 18, 2026, last Jul 28, 2026. Jim Wassil, CHIEF OPERATING OFFICER → EVP, Chief Scientific Ofc, COO: sold $3.1M across 10 filings, first filed Mar 11, 2026, last Oct 7, 2026. Elvia Cowan, SVP, FINANCE → SVP, Finance & CAO: sold $2.6M across 5 filings, first filed Dec 29, 2025, last Oct 7, 2026. Andrew Guggenhime, PRESIDENT AND CFO: sold $1.6M across 3 filings, first filed Jun 18, 2026, last Aug 5, 2026. Harpreet S. Dhaliwal, Chief Technical Ops Officer: sold $1.4M across 2 filings, first filed Jan 2, 2026, last Aug 5, 2026.
Largest mark · tap a row for others
Jim Wassil · EVP, Chief Scientific Ofc, COO
Filing 1 of 2 within a week · $1,688,833 total
Sale $127,513
2,250 shares at $56.67 avg
Filed Oct 2, 2026 · traded Oct 1
Pre-arranged (10b5-1) · close on filing date $56.48
Grant Pickering · CHIEF EXECUTIVE OFFICER
CHIEF EXECUTIVE OFFICER
$3.6M soldJim Wassil · CHIEF OPERATING OFFICER → EVP, Chief Scientific Ofc, COO
CHIEF OPERATING OFFICER → EVP, Chief Scientific Ofc, COO
$3.1M soldElvia Cowan · SVP, FINANCE → SVP, Finance & CAO
SVP, FINANCE → SVP, Finance & CAO
$2.6M soldAndrew Guggenhime · PRESIDENT AND CFO
PRESIDENT AND CFO
$1.6M soldHarpreet S. Dhaliwal · Chief Technical Ops Officer
Chief Technical Ops Officer
$1.4M soldOpen-market trades
23 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER | $3.6M | — | 3 | 100% of sales | |
| Jim Wassil | CHIEF OPERATING OFFICER → EVP, Chief Scientific Ofc, COO | $3.1M | — | 10 | 88% of sales | |
| Elvia Cowan | SVP, FINANCE → SVP, Finance & CAO | $2.6M | — | 5 | 79% of sales | |
| Andrew Guggenhime | PRESIDENT AND CFO | $1.6M | — | 3 | 100% of sales | |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | $1.4M | — | 2 | 67% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Jim Wassil EVP, Chief Scientific Ofc, COO | SalePre-arranged (10b5-1) | 18,000 | $86.74 | $1.6M | 145,435 | |
traded | Elvia Cowan SVP, Finance & CAO | SalePre-arranged (10b5-1) | 19,000 | $86.74 | $1.6M | 27,860 | |
traded | Jim Wassil EVP, Chief Scientific Ofc, COO | SalePre-arranged (10b5-1) | 2,250 | $56.67 | $127.5K | 145,435 | |
traded | Jim Wassil EVP, Chief Scientific Ofc, COO | Sale | 2,715 | $60.35 | $163.9K | 145,435 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | Sale | 3,477 | $61.07 | $212.4K | 156,981 | |
traded | Andrew Guggenhime PRESIDENT AND CFO | SalePre-arranged (10b5-1) | 10,000 | $53.89 | $538.9K | 105,176 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 2,250 | $53.86 | $121.2K | 157,541 | |
traded | Harpreet S. Dhaliwal Chief Technical Ops Officer | SalePre-arranged (10b5-1) | 17,000 | $55.00 | $935.1K | 76,756 | |
traded | Grant Pickering CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 18,198 | $55.63 | $1.0M | Multiple accounts | |
traded | Andrew Guggenhime PRESIDENT AND CFO | SalePre-arranged (10b5-1) | 10,000 | $57.28 | $572.8K | 106,482 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 2,250 | $56.33 | $126.7K | 157,222 | |
traded | Grant Pickering CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 24,237 | $55.22 | $1.3M | Multiple accounts | |
traded | Andrew Guggenhime PRESIDENT AND CFO | SalePre-arranged (10b5-1) | 10,000 | $53.00 | $530.0K | 104,395 | |
traded | Grant Pickering CHIEF EXECUTIVE OFFICER | SalePre-arranged (10b5-1) | 24,461 | $52.50 | $1.3M | Multiple accounts | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 2,250 | $49.52 | $111.4K | 158,795 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 2,250 | $56.83 | $127.9K | 160,744 | |
traded | Elvia Cowan SVP, Finance & CAO | SalePre-arranged (10b5-1) | 3,000 | $60.00 | $180.0K | 28,975 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 2,250 | $58.43 | $131.5K | 162,994 | |
traded | Elvia Cowan SVP, Finance & CAO | SalePre-arranged (10b5-1) | 1,892 | $55.57 | $105.1K | 29,380 | |
traded | Jim Wassil CHIEF OPERATING OFFICER | SalePre-arranged (10b5-1) | 7,395 | $58.88 | $435.4K | 166,818 | |
traded | Elvia Cowan SVP, Finance & CAO | SalePre-arranged (10b5-1) | 2,500 | $58.59 | $146.5K | 30,867 | |
traded | Harpreet S. Dhaliwal Chief Technical Ops Officer | Sale | 9,743 | $46.69 | $454.9K | 23,928 | |
traded | Elvia Cowan SVP, FINANCE | Sale | 11,623 | $47.92 | $557.0K | 21,250 |
GET /stocks/filings/vX/form-4?tickers=PCVX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PCVX"
],
"issuer_cik": "0001649094",
"owner_cik": "0001813798",
"accession_number": "0001813798-26-000023",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-05",
"issuer_name": "Vaxcyte, Inc.",
"issuer_trading_symbol": "PCVX",
"owner_name": "Wassil Jim",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Chief Scientific Ofc, COO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 18000,
"transaction_price_per_share": 86.74,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 145435,
"transaction_value": 1561320,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025."
}
]
},
{
"tickers": [
"PCVX"
],
"issuer_cik": "0001649094",
"owner_cik": "0001960048",
"accession_number": "0001960048-26-000013",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-05",
"issuer_name": "Vaxcyte, Inc.",
"issuer_trading_symbol": "PCVX",
"owner_name": "Cowan Elvia",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "SVP, Finance & CAO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 19000,
"transaction_price_per_share": 86.74,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 27860,
"transaction_value": 1648060,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 66 records
- Option exercises15 records
- Tax withholding31 records
- Grants and awards16 records
- Gifts4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Vaxcyte, Inc.'s CEO sold stock?
Yes. Grant Pickering (CEO) sold 66,896 shares ($3.6M) between Jun 2026 and Jul 2026, all under a pre-arranged 10b5-1 plan.
How current is PCVX’s insider data?
These are PCVX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PCVX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PCVX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.